FDAsafety guidance66% confidence
FDA AP — PITOLISANT HYDROCHLORIDE (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Bristol Myers Squibb; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA218495. Sponsor: NOVITIUM PHARMA. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: PITOLISANT HYDROCHLORIDE.
Supporting Context
- Therapeutic area
- Hematology · Myelofibrosis
- Sub-indication
- General
Related signal: FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)